Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
23 trials match your criteria
Recruiting
Agitation+1
RecruitingInvestigational
A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
Investigational
- Disease:AgitationDementia Alzheimer's type
- Substances:Dextromethorphan Hydrobromide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Dextromethorphan Hydrobromide
Recruiting
Psychotic disorder+1
RecruitingInvestigationalNo placebo
Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer's-Related Psychosis
InvestigationalNo placebo
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Trospium Chloride
Recruiting
Triple negative breast cancer+4
RecruitingRegistered drugNo placebo
Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer
Registered drugNo placebo
- Disease:Triple negative breast cancerBreast cancer stage II+3
- Substances:PembrolizumabSacituzumab Govitecan
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Gastrectomy
RecruitingRegistered drug
Study on the Effects of Amylase, Protease, and Rizolipase for Patients After Gastrectomy
Registered drug
- Disease:Gastrectomy
- Substances:AmylaseProtease+1
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Amylase
Not yet recruiting
Relapsing-remitting multiple sclerosis
Not yet recruitingRegistered drugNo placebo
Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Relapsing-remitting multiple sclerosis
- Substances:Ocrelizumab
Countries:Germany
Germany- Participants:18–64 years
- Substances:Ocrelizumab
Not recruiting
Dementia Alzheimer's type
Not recruitingRegistered drug
Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type
Registered drug
- Disease:Dementia Alzheimer's type
- Substances:Semaglutide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Semaglutide
Not recruiting
Neuralgia+1
Not recruitingInvestigational
Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy
Investigational
- Disease:NeuralgiaPolyneuropathy
- Substances:LY3848575
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:LY3848575
Not recruiting
Migraine
Not recruitingInvestigational
Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments
Investigational
- Disease:Migraine
- Substances:Lu Ag09222
Countries:Germany
Germany- Participants:18–64 years
- Substances:Lu Ag09222
Not recruiting
Dementia Alzheimer's type
Not recruitingInvestigational
Study on the Effectiveness and Safety of AVP-786 (Quinidine Sulfate and Deudextromethorphan Hydrobromide) for Treating Agitation in Alzheimer's Dementia Patients
Investigational
- Disease:Dementia Alzheimer's type
- Substances:Quinidine SulfateDeudextromethorphan Hydrobromide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Quinidine Sulfate
Not recruiting
Schizophrenia
Not recruitingInvestigationalNo placebo
Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials
InvestigationalNo placebo
- Disease:Schizophrenia
- Substances:Iclepertin
Countries:Germany
Germany- Participants:18–64 years
- Substances:Iclepertin
Not recruiting
Relapsing multiple sclerosis
Not recruitingRegistered drug
Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:FenebrutinibTeriflunomide
Countries:Germany
Germany- Participants:18–64 years
- Substances:Fenebrutinib